REQUEST MORE INFORMATION
The dangerous side effects of Raptiva injection far outweigh the good it does to treat psoriasis. Which is worse a chronic skin disorder, or a fatal brain infection?
Psoriasis is a chronic and common skin disorder. Raptiva is a drug prescribed to treat the skin disorder. Raptiva is a once-weekly injection approved for adults with moderate to severe plaque psoriasis who are candidates for whole body therapy or phototherapy to control their psoriasis.
On February 19, 2009, the Food & Drug Administration announced that people who take Raptiva are at risk for developing a rare fatal condition known as PML or progressive multifocal leukoencephalopathy. The FDA issued a public health advisory concerning three confirmed, and one possible report of PML, a rare brain infection, in patients using the psoriasis drug Raptiva.Do You Have a Raptiva Psoriasis Drug Lawsuit? »
Three of those patients have died. All four patients were treated with Raptiva for more than three years. None of the patients were receiving other treatments that suppress the immune system.
PML is a brain disease that gets worse over time and can attack many parts of the brain at once. The brain infection is caused by a loss of white matter, a substance that protects nerve fibers in the brain. Without this white matter or myelin, nerve signals don't compute from the brain to the rest of the body.
PML is caused by the reactivation of a common virus in the central nervous system of immune-compromised persons. The JC virus is carried by a majority of people and is considered harmless except for persons with lowered immune defenses. PML is most common among people with acquired immune deficiency syndrome (AIDS).
Symptoms vary but are generally clumsiness, gradual but progressive weakness, and a change in visual acuity, speech, and personality. All lead to a quality of life threatening disability and decline leading to death...from taking a drug for psoriasis...a common skin condition.Contact Our Raptiva Lawyers Today »
EMEA (European Medicines Agency), Europe's version of the FDA announced that the risks of Raptiva outweigh the benefits and should no longer be prescribed.